Glomeria win an Horizon 2020 SME Phase 2 Grant for € 2.8 Million!

Glomeria Therapeutics has been recently notified by the European Commission as a selected winner of a Grant on the Horizon 2020 – SME Instrument Phase 2 for approximately € 2.8 million.The TheraPD project presented by Glomeria has the main objective to move from prototype to a full scale production industrialized Platform for Peritoneal Dialysis (PD) Therapy on End Stage Renal Disease (ESRD) Patients, with a very innovative technology that will significantly enhance the efficacy and efficiency level of the dialysis session as well the safety level for all patients undergoing to PD.

2.7 million People worldwide (250,000 Europeans) have kidney transplants or undergo a dialysis treatment because of irreversible end-stage renal disease (ESRD). This number has more than doubled over the past 15 years and involves 3-5% of NHS budgets. Current therapy consist in either a kidney transplant, haemodialysis connected to a machine at the hospital for 3-5h, three times a week, or the better-outcome cost-effective home-based daily peritoneal dialysis (PD). Although widely demonstrated to have greater results and to be cost-effective, PD is only used in 11% of the cases because of its drawbacks: peritonitis (approx. 35% drop-out), poorly biocompatible PD solutions available, and over-filling of the peritoneal cavity causing damage and rapid degradation on the mesothelium membrane.

The core innovative technology of TheraPD provides the most safe and efficient automated peritoneal dialysis therapy to date. It entails a comprehensive system that is based on three main aspects:

  • the sterile connection capability of the DesmoPD connector that allows a truly sterile connection of the peritoneal catheter and the PD disposable devices almost zeroing the risk of peritonites due to bacterial contamination during daily frequent connections.
  • a biosensing control system based on the pressure control automatic cycling system to manage the filling and draining of the peritoneal cavity with the osmotic agent, thus preventing damage and rapid degradation to the peritoneal membrane avoiding overfilling and cavitation and specialbiosensors capable of measuring the concentration of glucose and pH; this allows to “personalize” the dialysis prescription according to the ultrafiltration capacity of the patient and it increases the safety level of the treatment allowing to monitor the uptake of glucose by the patient.
  • a new biocompatible dialysate for preventing rapid degradation of peritoneal membrane cells.

By solving these unmet clinical needs through innovation, we will increase PD usage by expanding it to people who were not previously eligible, reduce treatment frequency or duration, customize the dialysis treatment (personalized) according to the response of the patient’s body, increase patients’ comfort and significantly reduce healthcare spending.

Fonte: Andrea Zanella – Linkedin

Leggi l’articolo

D-Orbit, la startup italiana operante nel settore spaziale in particolare nell’ambito del recupero di satelliti spaziali (decommissioning), annuncia il closing di un nuovo round di investimento. Nessuna disclosure sulle cifre. – See more at: